

**Remarks**


The amendments to the specification are being made to update the priority data, to insert the heading "Brief Description of the Drawings," to insert references to the subfigures of Figure 2, to insert sequence identifiers, and to add the abstract of the disclosure. Applicants respectfully submit that no new matter has been added by these amendments.

Figure 5 has been amended to delete the sequence for VhhM-1C8 (see attached replacement sheet for Figure 5). Thus, page 19, line 19 and page 20, line 1 of the specification have been amended accordingly. The statement inserted on page 19, line 36, clarifies that three melamine-binding proteins were isolated from the antibody library and sequenced, although only two of the sequences are disclosed in Figure 5. Support for this statement can be found on page 19, lines 18-20, as originally filed.

**Except** for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or to credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: May 15, 2007  
Morgan, Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
202-739-3000

Respectfully submitted,  
**Morgan, Lewis & Bockius LLP**

  
Sally P. Teng  
Registration No. 45,397